,43 Other arguments for the use of BTA are small, hypothesis generating, in vivo (N = 62–129) and in vitro series that reveal synergy between bisphosphonates and EGFR TKIs with effects on tumor suppression, PFS, and OS post-bone metastases.44, 45, 46 This synergistic effect should be evaluated prospectively. This evidence concerns the gene EGFR and neoplasm.